The experience of interferon-based treatments for hepatitis C infection

Qualitative Health Research

Volumn 15, Issue 5, 2005, Pages 635-646

  Hopwood, Max ^a   Treloar, Carla ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Hepatitis C treatment; Interferon; Quality of life; Side effects

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY DISORDER; ARTICLE; AUSTRALIA; CARDIOTOXICITY; CLINICAL ARTICLE; DEPRESSION; DRUG INDUCED HEADACHE; DRY EYE; DYSPNEA; EDEMA; EXPERIENCE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEART FIBRILLATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETHARGY; LIVER PAIN; MALE; MENTAL DISEASE; MIGRAINE; MOOD DISORDER; PAIN; PREDICTION; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SUICIDAL BEHAVIOR; THORAX PAIN; VERTICAL TRANSMISSION; DRUG CONTRAINDICATION; HEART ARREST; INTERVIEW; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEART ARREST; HEPATITIS C; HUMANS; INTERFERONS; INTERVIEWS; MALE; MIDDLE AGED; NEW SOUTH WALES; QUALITATIVE RESEARCH; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 21744450449     PISSN: 10497323     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049732304273932     Document Type: Article

References (34)

1. Australian National Council on AIDS, Hepatitis C and Related Diseases (ANCAHRD) Hepatitis C Sub-Committee. (2002). Hepatitis C virus projections working group: Estimates and projections of the hepatitis C virus epidemic in Australia. Sydney, Australia: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.
2. Baer, M. R., & Roberts, J. (2002). Complex HIV treatment regimens and patient quality of life. Canadian Psychology, 43, 115-121.
3. Bonaccorso, S., Marino, V., Biondi, M., Grimaldi, F., Ippoliti, F., & Maes, M. (2002). Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. Journal of Affective Disorders, 72, 237-241.
4. Bonkovsky, H. L., Woolley, J. M., & the Consensus Interferon Study Group. (1999). Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology, 29, 264-270.
5. Carithers, R. L., Sugano, D., & Bayliss, M. (1996). Health assessment for chronic HCV infection: Results of quality of life. Digestive Diseases and Sciences, 41(12 Suppl.), 75S-80S.
6. Clemensen, L. R., Eshelman, A. K., & Belville-Robertson, T. L. (1999). Psychiatric and behavioural side effects of alpha interferon for treatment of hepatitis C: A review [Abstracts of papers for 1999 Annual Meeting]. Psychosomatic Medicine, 61, 102.
7. Crofts, N. (2001). Descriptive epidemiology of the hepatitis C virus. In N. Crofts, G. Dore, & S. Locarnini (Eds.), Hepatitis C: An Australian perspective (pp. 220-245). Melbourne, Australia: IP Communications.
8. Crofts, N., Dore, G., & Locarnini, S. (2001). Preface. In N. Crofts, G. Dore, & S. Locarnini (Eds.), Hepatitis C: An Australian perspective (pp. xv-xviii). Melbourne, Australia: IP Communications.
9. Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., et al. (1994). Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clinical Therapeutics, 16, 334-343.
10. Dieperink, E., Ho, S. B., Thuras, P., & Willenbring, M. L. (2003). A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics, 44, 104-112.
11. Dore, G. (2001). Therapy decision making for people with chronic hepatitis C. In N. Crofts, G. Dore, & S. Locarnini (Eds.), Hepatitis C: An Australian perspective (pp. 172-182). Melbourne, Australia: IP Communications.
12. Dore, G. (2003, October). The public health implications of the hepatitis C epidemic in Australia. Paper presented at 15th Annual Conference of the Australasian Society for HIV Medicine - Global Crisis: Local Action, Cairns, Australia.
13. Everson, G. T., & Weinberg, H. (1999). Living with hepatitis C: A survivor's guide (Rev. ed.). New York: Hatherleigh.
14. Fried, M. W. (2002). Side effects of therapy of hepatitis C and their management. Hepatology, 36(Suppl. 1), S237-S244.
15. Grbich, C. (1999). Qualitative research in health: An introduction. St. Leonards, Australia: Allen and Unwin.
16. Hopwood, M. (2003). New treatment for hepatitis C infection. Social Research Briefs, 3. Retrieved December 10, 2003, from http://nchsr.arts.unsw.edu.au/social_research_briefs.html
17. Hopwood, M., & Southgate, E. (2003). Living with hepatitis C: A sociological review. Critical Public Health, 13, 251-267.
18. Hopwood, M., & Treloar, C. (2003). The 3D Project: Diagnosis, disclosure, discrimination and living with hepatitis C (Monograph 6/2003). Sydney, Australia: National Centre in HIV Social Research, University of New South Wales.
19. Janssen, H. L. A., Brouwer, J. T., van der Mast, R. C., & Schalm, S. W. (1994). Suicide associated with alfa-interferon therapy for chronic viral hepatitis. Journal of Hepatology, 21, 241-243.
20. Keating, G. M., & Curran, M. P. (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: A review of its use in the management of chronic hepatitis C [Review]. Drugs, 63, 701-730.
21. Kleinman, A. (1988). The illness narratives: Suffering, healing and the human condition. New York: Basic Books.
22. Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M. (2003). Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. Journal of Clinical Psychiatry, 64, 708-714.
23. Lai, M. Y. (2000). Firstline treatment for hepatitis C: Combination interferon/ribavirin versus interferon monotherapy. Journal of Gastroenterology and Hepatology, 15(Suppl. 2), E130-13133.
24. Law, M. G. (2003, May). Estimates and projections of the hepatitis C epidemic in Australia. Paper presented at the National Centre in HIV Social Research Blood Awareness Forum, Sydney, Australia.
25. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., et al. (2001). Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. The Lancet, 358, 958-965.
26. Montessori, V., Press, N., Harris, M., Akagi, L., & Montaner, J. S. G. (2004). Adverse effects of anti-retroviral therapy for HIV infection. Canadian Medical Association Journal, 170, 229-238.
27. National Centre in HIV Epidemiology and Clinical Research. (2002). HIV/AIDS, hepatitis C and sexually transmissible infections in Australia: Annual surveillance report 2002. Sydney, Australia: Author.
28. Persson, A. (in press). Incorporating pharmakon: HIV, medicine and body shape change. Body & Society.
29. Race, K., & Wakeford, E. (2000). Dosing on time: Developing adherent practice with highly active anti-retroviral therapy. Culture, Health & Sexuality, 2, 213-228.
30. Rasenack, J., Zeuzem, S., Feinman, S. V., Heathcote, E. J., Manns, M., Yoshida, E. M., et al. (2003). Peginterferon alpha-2a (40kD) (Pegasys) improves HR-QOL outcomes compared with unmodified interferon alpha-2a (Roferon-A) in patients with chronic hepatitis C. Pharmacoeconomics, 21, 341-349.
31. Sievert, W. (2001). An overview of anti-viral therapy for chronic hepatitis C infection. In N. Crofts, G. Dore, & S. Locarnini (Eds.), Hepatitis C: An Australian perspective (pp. 140-154). Melbourne, Australia: IP Communications.
32. Sladden, T. J., Hickey, A. R., Dunn, T. M., & Beard, J. R. (1997). Hepatitis C transmission on the north coast of New South Wales: Explaining the unexplained. Medical Journal of Australia, 166, 290-293.
33. Terrault, N. A. (2002). Sexual activity as a risk factor for hepatitis C. Hepatology, 36(Suppl.), S99-S105.
34. Wodak, A. (1998). Do injecting drug users in Australia need education about hepatitis C? Hepatitis See, 1/2, 5.